PTC Therapeutics, Inc. Operating Expenses
PTC Therapeutics, Inc. (PTCT) reported Operating Expenses of $211.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-30
- PTC Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $211.54M, a 1.07% decline year-over-year.
- PTC Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $227.59M, a 10.55% increase year-over-year.
- PTC Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $236.03M, a 37.15% decline year-over-year.
- PTC Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $207.99M, a 17.23% decline year-over-year.
- PTC Therapeutics, Inc. operating expenses for fiscal 2025 was $863.72M, a 22.14% decline from fiscal 2024.
- PTC Therapeutics, Inc. operating expenses for fiscal 2024 was $1.11B, a 19.46% decline from fiscal 2023.
- PTC Therapeutics, Inc. operating expenses for fiscal 2023 was $1.38B, a 20.16% increase from fiscal 2022.
- PTC Therapeutics, Inc. operating expenses for fiscal 2022 was $1.15B, a 25.54% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $211.54M 10-Q · filed 2026-07-30 | $439.13M 10-Q · filed 2026-07-30 | $675.16M derived: sum of 3 quarters · filed 2026-07-30 | $883.15M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $227.59M 10-Q · filed 2026-05-07 | $463.62M derived: sum of 2 quarters · filed 2026-05-07 | $671.61M derived: sum of 3 quarters · filed 2026-05-07 | $885.44M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $236.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $444.02M derived: sum of 2 quarters · filed 2026-02-19 | $657.85M derived: sum of 3 quarters · filed 2026-07-30 | $863.72M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $207.99M 10-Q · filed 2025-11-04 | $421.82M derived: sum of 2 quarters · filed 2026-07-30 | $627.69M 10-Q · filed 2025-11-04 | $1.00B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $213.83M 10-Q · filed 2026-07-30 | $419.70M 10-Q · filed 2026-07-30 | $795.26M derived: sum of 3 quarters · filed 2026-07-30 | $1.05B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $205.87M 10-Q · filed 2026-05-07 | $581.43M derived: sum of 2 quarters · filed 2026-05-07 | $832.73M derived: sum of 3 quarters · filed 2026-05-07 | $1.06B derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $375.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $626.86M derived: sum of 2 quarters · filed 2026-02-19 | $853.78M derived: sum of 3 quarters · filed 2026-02-19 | $1.11B 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | $251.30M 10-Q · filed 2025-11-04 | $478.22M derived: sum of 2 quarters · filed 2025-11-04 | $733.79M 10-Q · filed 2025-11-04 | $1.04B derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | $226.92M 10-Q · filed 2025-08-07 | $482.49M 10-Q · filed 2025-08-07 | $783.73M derived: sum of 3 quarters · filed 2026-02-19 | $1.10B derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $255.57M 10-Q · filed 2025-05-06 | $556.81M derived: sum of 2 quarters · filed 2026-02-19 | $871.55M derived: sum of 3 quarters · filed 2026-02-19 | $1.29B derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $301.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $615.98M derived: sum of 2 quarters · filed 2026-02-19 | $1.04B derived: sum of 3 quarters · filed 2026-02-19 | $1.38B 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $314.74M 10-Q · filed 2024-11-07 | $738.09M derived: sum of 2 quarters · filed 2024-11-07 | $1.08B 10-Q · filed 2024-11-07 | $1.44B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $423.35M 10-Q · filed 2024-08-08 | $761.35M 10-Q · filed 2024-08-08 | $1.13B derived: sum of 3 quarters · filed 2025-02-27 | $1.41B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $338.00M 10-Q · filed 2024-04-25 | $705.75M derived: sum of 2 quarters · filed 2025-02-27 | $991.06M derived: sum of 3 quarters · filed 2025-02-27 | $1.25B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $367.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $653.07M derived: sum of 2 quarters · filed 2025-02-27 | $910.96M derived: sum of 3 quarters · filed 2025-02-27 | $1.15B 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $285.31M 10-Q · filed 2023-10-26 | $543.20M derived: sum of 2 quarters · filed 2023-10-26 | $778.46M 10-Q · filed 2023-10-26 | $1.03B derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $257.89M 10-Q · filed 2023-08-03 | $493.14M 10-Q · filed 2023-08-03 | $743.10M derived: sum of 3 quarters · filed 2024-02-29 | $974.92M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | $235.26M 10-Q · filed 2023-04-27 | $485.22M derived: sum of 2 quarters · filed 2024-02-29 | $717.03M derived: sum of 3 quarters · filed 2024-02-29 | $932.20M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $249.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $481.78M derived: sum of 2 quarters · filed 2024-02-29 | $696.95M derived: sum of 3 quarters · filed 2024-02-29 | $913.04M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $231.82M 10-Q · filed 2022-10-27 | $446.99M derived: sum of 2 quarters · filed 2022-10-27 | $663.08M 10-Q · filed 2022-10-27 | $878.32M derived: sum of 4 quarters · filed 2022-10-27 | ||||
| 2021-06-30 | $215.17M 10-Q · filed 2022-08-04 | $431.26M 10-Q · filed 2022-08-04 | $646.50M derived: sum of 3 quarters · filed 2022-08-04 | $820.03M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $216.09M 10-Q · filed 2022-05-03 | $431.33M derived: sum of 2 quarters · filed 2022-05-03 | $604.86M derived: sum of 3 quarters · filed 2022-05-03 | $867.38M derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2020-12-31 | $215.24M 10-K · filed 2021-02-25 | $388.77M derived: sum of 2 quarters · filed 2021-10-28 | $651.28M derived: sum of 3 quarters · filed 2021-10-28 | $812.53M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | $173.53M 10-Q · filed 2021-10-28 | $436.05M derived: sum of 2 quarters · filed 2021-10-28 | $597.30M 10-Q · filed 2021-10-28 | $766.54M derived: sum of 4 quarters · filed 2021-10-28 | ||||
| 2020-06-30 | $262.51M 10-Q · filed 2021-07-29 | $423.76M 10-Q · filed 2021-07-29 | $593.00M derived: sum of 3 quarters · filed 2021-07-29 | $724.90M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | $161.25M 10-Q · filed 2021-05-04 | $330.49M derived: sum of 2 quarters · filed 2021-05-04 | $462.38M derived: sum of 3 quarters · filed 2021-05-04 | $586.66M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | $169.24M 10-K · filed 2021-02-25 | $301.13M derived: sum of 2 quarters · filed 2021-02-25 | $425.41M derived: sum of 3 quarters · filed 2021-02-25 | $548.14M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | $131.89M 10-K · filed 2021-02-25 | $256.17M derived: sum of 2 quarters · filed 2021-02-25 | $378.89M 10-Q · filed 2020-10-29 | $510.37M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $124.28M 10-K · filed 2021-02-25 | $247.00M 10-Q · filed 2020-08-05 | $378.48M derived: sum of 3 quarters · filed 2021-02-25 | $480.30M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $122.72M 10-K · filed 2021-02-25 | $254.20M derived: sum of 2 quarters · filed 2021-02-25 | $356.02M derived: sum of 3 quarters · filed 2021-02-25 | $430.34M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $131.48M 10-K · filed 2020-03-02 | $233.30M derived: sum of 2 quarters · filed 2020-03-02 | $307.61M derived: sum of 3 quarters · filed 2020-03-02 | $380.42M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $101.82M 10-K · filed 2020-03-02 | $176.14M derived: sum of 2 quarters · filed 2020-03-02 | $248.94M 10-Q · filed 2019-10-30 | $321.52M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $74.32M 10-K · filed 2020-03-02 | $147.12M 10-Q · filed 2019-08-06 | $219.70M derived: sum of 3 quarters · filed 2020-03-02 | $292.44M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $72.81M 10-K · filed 2020-03-02 | $145.38M derived: sum of 2 quarters · filed 2020-03-02 | $218.13M derived: sum of 3 quarters · filed 2020-03-02 | $278.59M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $72.58M 10-K · filed 2019-03-01 | $145.32M derived: sum of 2 quarters · filed 2019-03-01 | $205.78M derived: sum of 3 quarters · filed 2019-03-01 | $258.68M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $72.75M 10-K · filed 2019-03-01 | $133.20M derived: sum of 2 quarters · filed 2019-03-01 | $186.10M 10-Q · filed 2018-11-05 | $236.29M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $60.46M 10-K · filed 2019-03-01 | $113.36M 10-Q · filed 2018-08-07 | $163.54M derived: sum of 3 quarters · filed 2019-03-01 | $218.59M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $52.90M 10-K · filed 2019-03-01 | $103.08M derived: sum of 2 quarters · filed 2019-03-01 | $158.13M derived: sum of 3 quarters · filed 2019-03-01 | $210.33M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $50.18M 10-K · filed 2018-03-06 | $105.23M derived: sum of 2 quarters · filed 2018-03-06 | $157.43M derived: sum of 3 quarters · filed 2018-03-06 | $214.76M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $55.05M 10-K · filed 2018-03-06 | $107.24M derived: sum of 2 quarters · filed 2018-03-06 | $164.58M 10-Q · filed 2017-11-02 | $225.51M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-06-30 | $52.19M 10-K · filed 2018-03-06 | $109.53M 10-Q · filed 2017-08-09 | $170.47M derived: sum of 3 quarters · filed 2018-03-06 | $222.47M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | $57.34M 10-K · filed 2018-03-06 | $118.27M derived: sum of 2 quarters · filed 2018-03-06 | $170.28M derived: sum of 3 quarters · filed 2018-03-06 | $215.68M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2015-12-31 | $60.94M 10-K · filed 2017-03-16 | $112.94M derived: sum of 2 quarters · filed 2017-03-16 | $158.34M derived: sum of 3 quarters · filed 2017-03-16 | $203.90M 10-K · filed 2018-03-06 | ||||
| 2015-09-30 | $52.01M 10-K · filed 2017-03-16 | $97.41M derived: sum of 2 quarters · filed 2017-03-16 | $142.96M 10-Q · filed 2016-11-03 | $187.85M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $45.40M 10-K · filed 2017-03-16 | $90.95M 10-Q · filed 2016-08-04 | $135.84M derived: sum of 3 quarters · filed 2017-03-16 | $165.14M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $45.55M 10-K · filed 2017-03-16 | $90.44M derived: sum of 2 quarters · filed 2017-03-16 | $119.74M derived: sum of 3 quarters · filed 2017-03-16 | $146.78M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | $44.89M 10-K · filed 2016-02-29 | $74.18M derived: sum of 2 quarters · filed 2016-02-29 | $101.23M derived: sum of 3 quarters · filed 2016-02-29 | $124.66M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $29.30M 10-K · filed 2016-02-29 | $56.34M derived: sum of 2 quarters · filed 2016-02-29 | $79.77M 10-Q · filed 2015-11-09 | $102.27M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $27.05M 10-K · filed 2016-02-29 | $50.48M 10-Q · filed 2015-07-31 | $72.98M derived: sum of 3 quarters · filed 2016-02-29 | $93.54M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $23.43M 10-K · filed 2016-02-29 | $45.93M derived: sum of 2 quarters · filed 2016-02-29 | $66.50M derived: sum of 3 quarters · filed 2016-02-29 | $87.80M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $22.50M 10-K · filed 2015-03-02 | $22.50M 10-K · filed 2014-03-06 | $43.07M derived: sum of 2 quarters · filed 2015-03-02 | $64.38M derived: sum of 3 quarters · filed 2015-03-02 | $80.09M 10-K · filed 2016-02-29 | $80.09M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | $20.57M 10-K · filed 2015-03-02 | $20.57M 10-Q · filed 2013-11-14 | $41.87M derived: sum of 2 quarters · filed 2015-03-02 | $57.59M 10-Q · filed 2014-11-06 | $57.59M 10-Q · filed 2013-11-14 | $70.26M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $21.31M 10-K · filed 2015-03-02 | $21.31M 10-Q · filed 2013-08-13 | $37.02M 10-Q · filed 2014-08-07 | $37.03M 10-Q · filed 2013-08-13 | $49.70M derived: sum of 3 quarters · filed 2015-03-02 | $63.95M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $15.72M 10-K · filed 2015-03-02 | $15.72M 10-K · filed 2014-03-06 | $28.39M derived: sum of 2 quarters · filed 2015-03-02 | $42.64M derived: sum of 3 quarters · filed 2015-03-02 | $57.73M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $12.67M 10-K · filed 2014-03-06 | $26.92M derived: sum of 2 quarters · filed 2014-03-06 | $42.01M derived: sum of 3 quarters · filed 2014-03-06 | $60.75M 10-K · filed 2015-03-02 | $60.75M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | $14.25M 10-K · filed 2014-03-06 | $29.33M derived: sum of 2 quarters · filed 2014-03-06 | $48.08M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | $15.08M 10-K · filed 2014-03-06 | $33.83M 10-Q · filed 2013-08-13 | ||||||
| 2012-03-31 | $18.75M 10-K · filed 2014-03-06 | |||||||
| 2011-12-31 | $74.83M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |